UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 8.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 298,454 shares of the biotechnology company’s stock after selling 27,428 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.21% of Aurinia Pharmaceuticals worth $2,188,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Stonepine Capital Management LLC bought a new position in shares of Aurinia Pharmaceuticals in the second quarter worth about $1,713,000. Price T Rowe Associates Inc. MD lifted its holdings in Aurinia Pharmaceuticals by 15.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 38,952 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 5,079 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Aurinia Pharmaceuticals in the 3rd quarter worth about $3,330,000. SG Americas Securities LLC increased its position in shares of Aurinia Pharmaceuticals by 4,307.9% during the third quarter. SG Americas Securities LLC now owns 547,727 shares of the biotechnology company’s stock worth $4,015,000 after acquiring an additional 535,301 shares during the period. Finally, Algert Global LLC raised its stake in shares of Aurinia Pharmaceuticals by 106.8% during the second quarter. Algert Global LLC now owns 193,804 shares of the biotechnology company’s stock valued at $1,107,000 after acquiring an additional 100,104 shares in the last quarter. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Performance

AUPH stock opened at $9.37 on Monday. Aurinia Pharmaceuticals Inc. has a one year low of $4.71 and a one year high of $10.67. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -62.46 and a beta of 1.41. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The firm has a 50-day simple moving average of $8.03 and a two-hundred day simple moving average of $6.75.

Wall Street Analysts Forecast Growth

AUPH has been the subject of several research reports. StockNews.com cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Insider Activity at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Jeffrey Allen Bailey sold 4,557 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $8.43, for a total transaction of $38,415.51. Following the sale, the director now owns 13,356 shares in the company, valued at approximately $112,591.08. The trade was a 25.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.30% of the stock is currently owned by insiders.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.